

## FOR IMMEDIATE RELEASE

### MEDIA CONTACTS

Jeffrey Meshulam  
Profectus BioSciences  
443-743-1107  
[meshulam@profectusbiosciences.com](mailto:meshulam@profectusbiosciences.com)

Kevin Jurrens  
Garfield Group Public Relations  
215-867-8600 (x273)  
[kjurrens@garfieldgroup.com](mailto:kjurrens@garfieldgroup.com)

## **Profectus BioSciences executes an Assignment and License agreement with Wyeth for vaccines against HIV, HCV, HPV and HSV**

*Leading R&D company will continue research for both therapeutic and preventative vaccines of chronic viral diseases*

**Baltimore, MD, November 10, 2008** - Profectus BioSciences, Inc. (Profectus) announced today that it has executed an Assignment and License Agreement with Wyeth Pharmaceuticals that provides Profectus therapeutic/prophylactic vaccine programs for Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Human Papilloma Virus (HPV) and Herpes Simplex Virus (HSV). These programs combine the Wyeth proprietary technologies in the fields of DNA and vectored vaccines used alone and in a prime-boost strategy to prevent and treat infections.

The Agreement also provides Profectus with access to an extensive portfolio of intellectual property, research reagents, equipment, governmental funding and clinical trial products.

“Bringing the Wyeth portfolio into Profectus boosts our ability to develop innovative ways to treat patients inflicted with some of the most destructive viral diseases of our day,” said Profectus President & CEO Shawn O’Brien. “The breadth and strength of the Wyeth portfolio, coupled with our expertise, will enable us to deliver a new class of vaccines into infected individuals with the first human trials projected to begin in 2009 for HIV followed closely by HCV. We are proud and honored to be the recipient of this portfolio and look forward to advancing this exciting class of vaccines to reduce morbidity and mortality.”

The newly formed world-class team has over 150 years of combined experience in developing and delivering vaccines. One notable addition is John Eldridge, Ph.D., former VP of Wyeth Vaccines who joined Profectus as CSO, Vaccines.

### **About Profectus BioSciences Inc.**

Profectus Biosciences is an R&D company dedicated to harnessing the immune system to prevent and treat chronic viral diseases and cancers through the delivery of proprietary prime/boost vaccines and small molecules. Profectus BioSciences Inc. commenced operations in early 2005. For more information please visit: [www.profectusbiosciences.com](http://www.profectusbiosciences.com).